Androgen deprivation therapy and the risk of tenosynovitis in prostate cancer patients

Abstract

Objectives

Androgen deprivation therapy (ADT) use in prostate cancer (PCa) patients has been reported to have an association with rheumatoid arthritis. We aimed to assess the impact of ADT on the subsequent risk of tenosynovitis.

Methods

Using data from the National Health Insurance Research Database of Taiwan between 2001 and 2013, 3309 patients with PCa were identified. Among them, 729 ADT patients comprised the study group with 729 matched non-ADT controls. We used a 1:1 propensity score matched analysis. The demographic characteristics and comorbidities of the patients were analyzed; Cox proportional hazards regression was used to calculate the hazard ratios (HR) for the risk of tenosynovitis.

Results

There were 224 (15.3%) patients with newly diagnosed tenosynovitis. Compared with non-ADT patients, ADT patients had a lower risk of subsequent tenosynovitis with an adjusted HR of 0.38 [95% confidence interval (CI) 0.28–0.51; P < 0.001].

Conclusions

ADT use apparently did not increase the risk of tenosynovitis in patients with PCa. Further studies are warranted to assess the clinical significance.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2

Abbreviations

CI:

Confidence interval

ADT:

Androgen deprivation therapy

PCa:

Prostate cancer

HR:

Hazard ratio

NHIRD:

National Health Insurance Research Database

NHI:

National Health Insurance

CVA:

Cerebral vascular accident

RA:

Rheumatoid arthritis

PSA:

Prostate-specific antigen

References

  1. 1.

    Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67(1):7–30

    Article  Google Scholar 

  2. 2.

    Huggins C, Hodges CV (1972) Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin 22(4):232–240

    Article  CAS  PubMed  Google Scholar 

  3. 3.

    Shahani S, Braga-Basaria M, Basaria S (2008) Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis. J Clin Endocrinol Metab 93(6):2042–2049

    Article  CAS  PubMed  Google Scholar 

  4. 4.

    Galvão DA, Taaffe DR, Spry N, Joseph D, Newton RU (2009) Cardiovascular and metabolic complications during androgen deprivation: exercise as a potential countermeasure. Prostate Cancer Prostatic Dis 12(3):233–240

    Article  PubMed  Google Scholar 

  5. 5.

    Wu CT, Yang YH, Chen PC, Chen MF, Chen WC (2015) Androgen deprivation increases the risk of fracture in prostate cancer patients: a population-based study in Chinese patients. Osteoporos Int 26(9):2281–2290

    Article  CAS  PubMed  Google Scholar 

  6. 6.

    Aragon-Ching JB, Williams KM, Gulley JL (2007) Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer. Front Biosci 12:4957–4971

    Article  CAS  PubMed  Google Scholar 

  7. 7.

    Kalina JL, Neilson DS, Comber AP, Rauw JM, Alexander AS, Vergidis J, Lum J (2017) Immune modulation by androgen deprivation and radiation therapy: implications for prostate cancer immunotherapy. Cancers (Basel) 9(2):E13

    Article  CAS  Google Scholar 

  8. 8.

    Liu JM, Yu CP, Chuang HC, Wu CT, Hsu RJ (2019)Androgen deprivation therapy for prostate cancer and the risk of autoimmune diseases. Prostate Cancer Prostatic Dis (Epub ahead of print)

  9. 9.

    Yang DD, Krasnova A, Nead KT, Choueiri TK, Hu JC, Hoffman KE, Yu JB, Spratt DE, Feng FY, Trinh QD, Nguyen P (2018) Androgen deprivation therapy and risk of rheumatoid arthritis in patients with localized prostate cancer. Ann Oncol 29(2):386–391

    Article  CAS  PubMed  Google Scholar 

  10. 10.

    Klil-Drori AJ, Tascilar K, Yin H, Aprikian A, Bitton A, Azoulay L (2016) Androgen deprivation therapy and the incidence of inflammatory bowel disease in patients with prostate cancer. Am J Epidemiol 184(1):15–22

    Article  PubMed  PubMed Central  Google Scholar 

  11. 11.

    Khalkhali-Ellis Z, Handa RJ, Price RH Jr, Adams BD, Callaghan JJ, Hendrix MJ (2002) Androgen receptors in human synoviocytes and androgen regulation of interleukin 1beta (IL-1beta) induced IL-6 production: a link between hypoandrogenicity and rheumatoid arthritis? J Rheumatol 29(9):1843–1846

    CAS  PubMed  Google Scholar 

  12. 12.

    Denaro V, Ruzzini L, Longo UG, Franceschi F, De Paola B, Cittadini A, Maffulli N, Sgambato A (2010) Effect of dihydrotestosterone on cultured human tenocytes from intact supraspinatus tendon. Knee Surg Sports Traumatol Arthrosc 18(7):971–976

    Article  PubMed  Google Scholar 

  13. 13.

    Bureau of National Health Insurance DoH, Executive Yuan (2013) The National Health Insurance Statistics. http://www.nhi.gov.tw/English/webdata/webdata.aspx?menu=11&menu_id=296&webdata_id=1942&WD_ID=296. Accessed 18 Sept 2014

  14. 14.

    Liu JM, Lin PH, Hsu RJ, Chang YH, Cheng KC, Pang ST, Lin SK (2016) Complementary traditional Chinese medicine therapy improves survival in patients with metastatic prostate cancer. Medicine 95(31):e4475

    Article  PubMed  PubMed Central  Google Scholar 

  15. 15.

    Liu JM, Chen TH, Chuang HC, Wu CT, Hsu RJ (2018) Statin reduces the risk of dementia in diabetic patients receiving androgen deprivation therapy for prostate cancer. Prostate Cancer Prostatic Dis (Epub ahead of print)

  16. 16.

    Stahl S, Vida D, Meisner C, Lotter O, Rothenberger J, Schaller HE, Stahl AS (2013) Systematic review and meta-analysis on the work-related cause of de Quervain tenosynovitis: a critical appraisal of its recognition as an occupational disease. Plast Reconstr Surg 132(6):1479–1491

    CAS  PubMed  Google Scholar 

  17. 17.

    Zenone T, Boibieux A, Tigaud S, Fredenucci JF, Vincent V, Chidiac C, Peyramond D (1999) Non-tuberculous mycobacterial tenosynovitis: a review. Scand J Infect Dis 31(3):221–228

    Article  CAS  PubMed  Google Scholar 

  18. 18.

    Dehghan F, Muniandy S, Yusof A, Salleh N (2014) Sex-steroid regulation of relaxin receptor isoforms (RXFP1 & RXFP2) expression in the patellar tendon and lateral collateral ligament of female WKY rats. Int J Med Sci 11(2):180–191

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. 19.

    Marqueti RC, Prestes J, Paschoal M, Ramos OH, Perez SE, Carvalho HF, Selistre-de-Araujo HS (2008) Matrix metallopeptidase 2 activity in tendon regions: effects of mechanical loading exercise associated to anabolicandrogenic steroids. Eur J Appl Physiol 104(6):1087–1093

    Article  CAS  PubMed  Google Scholar 

  20. 20.

    Parssinen M, Karila T, Kovanen V, Seppälä T (2000) The effect of supraphysiological doses of anabolic androgenic steroids on collagen metabolism. Int J Sports Med 21(6):406–411

    Article  CAS  PubMed  Google Scholar 

  21. 21.

    Kaczmarek P, Pokoca L, Niemirowicz J, Majewska E, Baj Z (2008) Effect of luteinizing hormone-releasing hormone (LHRH) analogue treatment on a cytokine profile in prostate cancer patients. Pharmacol Rep 60(3):399–403

    CAS  PubMed  Google Scholar 

  22. 22.

    Salman H, Bergman M, Net Blumberger, Djaldetti M, Bessler H (2014) Do androgen deprivation drugs affect the immune cross-talk between mononuclear and prostate cancer cells? Biomed Pharmacother 68(1):21–24

    Article  CAS  PubMed  Google Scholar 

  23. 23.

    Sutherland JS, Goldberg GL, Hammett MV, Uldrich AP, Berzins SP, Heng TS, Blazar BR, Millar JL, Malin MA, Chidgey AP, Boyd RL (2005) Activation of thymic regeneration in mice and humans following androgen blockade. J Immunol 175(4):2741–2753

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This study was supported by the Taoyuan General Hospital, Ministry of Health and Welfare (Grant No. PYT10801) and Cross-institute Research Committee, Buddhist Tzu Chi Medical Foundation (TCMMP105-09-03).

Author information

Affiliations

Authors

Corresponding author

Correspondence to Ren-Jun Hsu.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Liu, JM., Liu, DW., Chuang, HC. et al. Androgen deprivation therapy and the risk of tenosynovitis in prostate cancer patients. Int Urol Nephrol 51, 1113–1119 (2019). https://doi.org/10.1007/s11255-019-02152-y

Download citation

Keywords

  • Prostate cancer
  • Tenosynovitis
  • Androgen deprivation therapy